Navigation Links
Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer Patients

CHICAGO, Nov. 2 /PRNewswire-USNewswire/ -- Short-term hormone therapy given prior to and during radiation treatment to medium-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone, however there is no significant benefit for low-risk patients, according to the largest randomized study of its kind presented at the plenary session November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

This phase III study is one of the largest clinical trials of prostate cancer therapy ever completed, with 2,000 low- and intermediate-risk patients enrolled in the trial from October 1994 to April 2001. Researchers from the Radiation Therapy Oncology Group (RTOG) followed men with early-stage prostate cancer for a period in most cases of more than nine years. This timeframe was sufficient to show improved survival benefits of short-term hormone therapy added to what was then the standard radiation treatment for prostate cancer, which involved slightly lower doses of radiation than are currently used today with newer techniques, such as intensity modulated radiation therapy (IMRT).

"The study provides strong scientific evidence that shows us when to deliver hormone therapy with radiation in patients with localized prostate cancer," Christopher U. Jones, M.D., an author of the study and a radiation oncologist at Radiological Associates of Sacramento in Sacramento, Calif., said. "Our findings show that men with low-risk disease, which is the vast majority of prostate cancer patients, have little to gain from adding hormone therapy to radiation. However, men with intermediate-risk disease, which is a significant minority of patients, gain a benefit in overall survival from the addition of only four months of hormone therapy. Prior to this trial, it was unclear whether or not combining hormone therapy with radiation for medium-risk prostate cancer patients improves survival."

Androgen deprivation therapy is hormone therapy used to treat prostate cancer by stopping or lowering the level of male hormones, or androgens, thereby removing the strongest growth factor for prostate cancer cells.

In the study, a total of 1,979 eligible men who had cancer confined to the prostate and a PSA less than or equal to 20 were randomized to receive total androgen deprivation therapy two months prior to and two months during radiation treatment, or radiation alone.

Findings show that short-term hormone therapy given to early-stage prostate cancer patients prior to and during radiation treatment significantly increases their chance of living longer (51 percent), compared to those who receive radiation alone (46 percent). Nearly all of the survival benefit was in the intermediate-risk group. Secondary endpoints of disease-free survival, freedom from biochemical failure, and positive two year re-biopsy rates were also better in the group who received short-term hormone therapy and radiation treatment.

The study was supported by grants from the National Cancer Institute.

For more information on radiation therapy for prostate cancer, visit

The abstract, "Short-Term Endocrine Therapy Prior To and During Radiation Therapy Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA <20: Initial Results of RTOG 94-08," will be presented at the plenary session at 2:15 p.m. on Monday, November 2, 2009. To speak to the presenter of the study, Christopher U. Jones, M.D., please call Beth Bukata or Nicole Napoli November 1-4, 2009, in the ASTRO Press Room at McCormick Place West at 312-791-7005 or 312-791-7006. You may also e-mail them at or

SOURCE American Society for Radiation Oncology

SOURCE American Society for Radiation Oncology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Short-Term, High-Dose Vitamin D2 May Ease Deficiency
2. After Tonsillectomy, Short-Term Antibiotics Effective: Study
3. Short-term stress enhances anti-tumor activity in mice, Stanford study shows
4. HIV Plus Alcohol Hampers Short-Term Memory
5. Demand for Short-Term Medical Help Leads to Growth for Travel Nursing Staffing Agency; Prompts Move to New Location and Addition of New Online Tools for Nurses
6. Chem Rx Corporation Extends Short-Term Forbearance Agreements with Lenders
7. Short-Term Air Pollution Exposure May Damage DNA
8. Chem Rx Corporation Enters Short-Term Forbearance Agreements With Lenders
9. Decoding short-term memory with fMRI
10. Assessing the real risk of heart disease in young people with low short-term risks
11. New data show patients using avonex reported less sick leave and short-term disability costs
Post Your Comments:
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: